Biodesix (BDSX) 주식 개요
바이오데식스는 진단 솔루션 기업으로 운영되고 있습니다. 자세히 보기
BDSX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Biodesix, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$14.93 |
| 52주 최고가 | US$20.21 |
| 52주 최저가 | US$5.00 |
| 베타 | 0.43 |
| 1개월 변동 | 40.32% |
| 3개월 변동 | 15.47% |
| 1년 변동 | 115.50% |
| 3년 변동 | -47.06% |
| 5년 변동 | -95.00% |
| IPO 이후 변동 | -94.17% |
최근 뉴스 및 업데이트
내러티브 업데이트 • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.
내러티브 업데이트 • Apr 16
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.Recent updates
내러티브 업데이트 • May 02
BDSX: Improved Balance Sheet And 2026 Revenue Outlook Will Support Upside
Analysts have lifted their price target on Biodesix to $73.88 from $57.08, citing above-expectation 2026 revenue guidance, three consecutive quarters of execution above target, and a "significantly improved" balance sheet that together support a higher assumed future P/E multiple. Analyst Commentary Recent research commentary points to a more constructive view on Biodesix, with bullish analysts highlighting the company’s 2026 revenue guidance, operating execution, and balance sheet as key reasons for a higher valuation framework.내러티브 업데이트 • Apr 16
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upgraded Rating
Analysts have nudged their price target on Biodesix higher to $30.00 from $30, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and three consecutive quarters of execution above target as reasons for a more constructive view. Analyst Commentary Bullish Takeaways Bullish analysts view the upgrade to an Outperform rating as a signal that recent execution and guidance support a higher valuation framework than before.내러티브 업데이트 • Apr 01
BDSX: Strong Guidance And Healthier Balance Sheet Will Support 2026 Momentum
Analysts have raised their price target on Biodesix from $30.00 to $56.14, citing 2026 revenue guidance that is 3% above prior expectations and a "significantly improved" balance sheet, with execution running above target for three consecutive quarters. Analyst Commentary Bullish Takeaways Bullish analysts point to the 2026 revenue guidance coming in 3% above prior expectations as support for a higher valuation range, given that it directly feeds into forward revenue estimates and P/S assumptions.
내러티브 업데이트 • Mar 18
BDSX: Improved Balance Sheet And 2026 Guidance Will Support Upside
Analysts have maintained their price target on Biodesix, citing 2026 revenue guidance that is 3% ahead of expectations, a "significantly improved" balance sheet, and what they see as three consecutive quarters of above target execution heading into 2026. Analyst Commentary The latest upgrade frames Biodesix as entering 2026 with momentum, supported by revenue guidance that sits 3% ahead of expectations and an improved balance sheet.내러티브 업데이트 • Mar 04
BDSX: Improved Balance Sheet And Guidance Will Support Momentum Into 2026
Analysts have reduced their price target on Biodesix from $35 to $30, citing updated fair value assumptions along with views that recent revenue guidance, improving margins, and a lower discount rate better reflect the company’s execution and balance sheet strength. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgrade to an Outperform rating as a sign that recent execution and guidance are more in line with what they view as fair value.내러티브 업데이트 • Feb 18
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have revised their price target on Biodesix to $40.00 from $40, reflecting updated views on discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Biodesix raised its revenue guidance for the fiscal year ending December 31, 2025, estimating total revenue of $88.5 million, above the previously increased range of $84 million to $86 million (company guidance).내러티브 업데이트 • Feb 02
BDSX: Raised 2025 Revenue Guidance Will Support Path To Profitability
Analysts have adjusted their price target on Biodesix to US$40.00 from US$40, citing updated assumptions around discount rates, revenue growth, profit margin, and future P/E that collectively refine, rather than overhaul, their previous view. What's in the News Biodesix issued new earnings guidance for the fourth quarter ended December 31, 2025, estimating total revenue of US$28.8 million for the period (Key Developments).내러티브 업데이트 • Jan 19
BDSX: Expanded Diagnostics Partnership Will Drive Revenue Upside In 2025
Analysts have increased their price target on Biodesix to reflect updated views on revenue growth potential and a slightly lower discount rate, while also adjusting expected profit margins and future P/E assumptions to align with their latest models. What's in the News Biodesix issued earnings guidance for the fourth quarter of 2025, estimating total revenue of $28.8 million for the period (Corporate guidance).분석 기사 • Jan 14
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump
Despite an already strong run, Biodesix, Inc. ( NASDAQ:BDSX ) shares have been powering on, with a gain of 26% in the...내러티브 업데이트 • Jan 05
BDSX: Expanded Diagnostics Partnership And ESR1 Assay Rollout Will Drive Upside
Analysts have lifted their price target on Biodesix to US$20.00 from US$1.50, citing adjusted assumptions around revenue growth, profit margin, discount rate, and a lower future P/E multiple as the key drivers of this revised view. What's in the News Biodesix raised its fiscal 2025 revenue guidance and now expects total revenue between US$84 million and US$86 million for the year (Key Developments).내러티브 업데이트 • Dec 14
BDSX: Reverse Split And ATM Access Will Support Path To Profitability
Analysts have significantly lifted their price target on Biodesix from $2.00 to $40.00, citing updated models following the 20 for 1 reverse split, a reduced share count, and the company’s ability to utilize its at the market facility to support operations through an expected path to cash flow breakeven and profitability. Analyst Commentary Bullish analysts interpret the new price target framework as a constructive signal for Biodesix, emphasizing that the reset reflects mechanical impacts from the 20 for 1 reverse split rather than a fundamental deterioration in the business outlook.분석 기사 • Nov 29
Biodesix, Inc.'s (NASDAQ:BDSX) Shares Leap 27% Yet They're Still Not Telling The Full Story
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...분석 기사 • Nov 05
US$32.50: That's What Analysts Think Biodesix, Inc. (NASDAQ:BDSX) Is Worth After Its Latest Results
Biodesix, Inc. ( NASDAQ:BDSX ) just released its latest quarterly results and things are looking bullish. Revenues and...분석 기사 • Sep 18
It's Down 27% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 27% over the previous 30 days, handing back...내러티브 업데이트 • Sep 16
Digital Integration And Expanded Lung Diagnostics Will Broaden Markets
The substantial increase in Biodesix’s consensus price target is accompanied by a modest improvement in forward earnings valuation and a slight rise in discount rate, indicating more favorable future expectations despite a marginally higher cost of capital, with fair value rising markedly to $35.00. What's in the News Biodesix announced a 1-for-20 stock split.분석 기사 • Jul 29
The Market Lifts Biodesix, Inc. (NASDAQ:BDSX) Shares 67% But It Can Do More
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 67% in the...분석 기사 • Jun 14
Biodesix, Inc. (NASDAQ:BDSX) Stock Rockets 30% But Many Are Still Ignoring The Company
Those holding Biodesix, Inc. ( NASDAQ:BDSX ) shares would be relieved that the share price has rebounded 30% in the...분석 기사 • May 15
Analysts Just Slashed Their Biodesix, Inc. (NASDAQ:BDSX) EPS Numbers
The latest analyst coverage could presage a bad day for Biodesix, Inc. ( NASDAQ:BDSX ), with the analysts making...분석 기사 • May 14
It's Unlikely That Biodesix, Inc.'s (NASDAQ:BDSX) CEO Will See A Huge Pay Rise This Year
Key Insights Biodesix's Annual General Meeting to take place on 20th of May Salary of US$588.9k is part of CEO Scott...분석 기사 • Apr 19
Investors Give Biodesix, Inc. (NASDAQ:BDSX) Shares A 33% Hiding
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 33% in the last...
새로운 내러티브 • Apr 03
Sales Force Expansion And CLARIFY Study Will Boost Test Adoption
Expansion of sales force and test adoption, along with CLARIFY study results, are expected to drive revenue growth and improve margins.분석 기사 • Mar 05
It's Down 30% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 30% in the last...분석 기사 • Jan 19
The Price Is Right For Biodesix, Inc. (NASDAQ:BDSX) Even After Diving 27%
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders that were waiting for something to happen have been dealt a blow with a 27...분석 기사 • Nov 21
With A 26% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 26% in the last...분석 기사 • Sep 24
Does Biodesix (NASDAQ:BDSX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • Jun 12
Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales...분석 기사 • Mar 03
With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For
The Biodesix, Inc. ( NASDAQ:BDSX ) share price has softened a substantial 25% over the previous 30 days, handing back...분석 기사 • Jan 04
Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce
Biodesix, Inc. ( NASDAQ:BDSX ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...분석 기사 • Jul 16
It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks
To the annoyance of some shareholders, Biodesix, Inc. ( NASDAQ:BDSX ) shares are down a considerable 28% in the last...주주 수익률
| BDSX | US Healthcare | US 시장 | |
|---|---|---|---|
| 7D | 7.1% | -0.3% | 1.2% |
| 1Y | 115.5% | 16.3% | 28.7% |
수익률 대 산업: BDSX은 지난 1년 동안 16.3%의 수익을 기록한 US Healthcare 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: BDSX은 지난 1년 동안 28.7%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| BDSX volatility | |
|---|---|
| BDSX Average Weekly Movement | 15.0% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: BDSX의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: BDSX의 주간 변동성(15%)은 지난 1년 동안 안정적이었지만 US 종목 중 상위 75%보다 높습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2005 | 334 | Scott Hutton | www.biodesix.com |
바이오데식스는 진단 솔루션 회사로 운영되고 있습니다. 이 회사는 폐암의 위험을 평가하고 적절한 치료 경로를 파악하는 데 도움을 주고 폐 결절이 의심되는 환자의 악성 위험을 재분류하는 데 의사를 돕는 Nodify 폐 결절 위험 평가 검사로서 Nodify XL2 및 Nodify CDT 검사 시장을 포함한 혈액 기반 폐 검사를 제공합니다. 또한 폐암 진단에서 종양의 돌연변이 유무와 환자의 면역 체계 상태를 측정해 치료 결정을 내리는 데 사용되는 진스트랫 ddPCR, 진스트랫 NGS, 베리스트랫 검사도 아이큐룽 검사 전략의 일환으로 시장에 공급하고 있다.
Biodesix, Inc. 기초 지표 요약
| BDSX 기초 통계 | |
|---|---|
| 시가총액 | US$150.92m |
| 순이익 (TTM) | -US$31.96m |
| 매출 (TTM) | US$96.10m |
1.6x
주가매출비율(P/S)-4.7x
주가수익비율(P/E)BDSX는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| BDSX 손익계산서 (TTM) | |
|---|---|
| 매출 | US$96.10m |
| 매출원가 | US$17.62m |
| 총이익 | US$78.48m |
| 기타 비용 | US$110.43m |
| 순이익 | -US$31.96m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -3.16 |
| 총이익률 | 81.66% |
| 순이익률 | -33.26% |
| 부채/자본 비율 | 509.1% |
BDSX의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/26 11:11 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Biodesix, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |